Weight Watchers Introduces Eli Lilly's New Oral GLP-1 Foundayo® via LillyDirect
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: moomoo
Product Launch: Weight Watchers has launched a new oral GLP-1 medication called Dayo® through its subsidiary, LILLY.
Availability: The new medication is available directly through the LILLY platform, expanding Weight Watchers' offerings in weight management solutions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 955.190
Low
950.00
Averages
1192
High
1500
Current: 955.190
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Foundayo Receives FDA Approval and Launches Nationwide
- Drug Launch: Eli Lilly announced that its weight loss medication Foundayo™ (orforglipron) received FDA approval on April 1, 2026, and became available through LillyDirect® and telehealth providers on April 9, marking a significant advancement in the weight loss market.
- Pricing and Accessibility: Foundayo is priced at $149 per month for self-pay patients, while eligible commercially insured patients can pay as little as $25 per month with a savings card, demonstrating Lilly's commitment to reducing patient burden and expanding drug accessibility.
- Clinical Trial Results: In the ATTAIN-1 clinical trial, patients on the highest dose lost an average of 27.3 pounds (12.4%), compared to only 2.2 pounds (0.9%) in the placebo group, indicating a significant advantage in weight loss efficacy that could enhance market acceptance.
- Health Risks and Side Effects: Foundayo may cause serious side effects, including thyroid tumors, requiring patients to be vigilant for symptoms; nevertheless, the drug's effectiveness and convenience continue to attract many seeking weight loss solutions.
See More
European Pharma Industry Faces Competitive Pressures
- Increased Market Competition: The European pharmaceutical industry is facing significant competitive pressures due to President Trump's drug pricing policies and the rise of China's biotech sector, leading to a shift in investments and impacting new drug launches.
- R&D Investment Shift: In 1990, Europe accounted for nearly half of global R&D, but this has plummeted to 26% today, while the U.S. share has risen to 55%, indicating a decline in Europe's position in global pharmaceutical innovation.
- Significant Policy Impact: The U.S. has imposed tariffs of up to 100% on branded drugs, which, while limited in immediate impact on companies without pricing agreements, adds to the competitive pressure on Europe's pharmaceutical sector, necessitating improvements in market conditions.
- Industry Calls for Reform: The European pharmaceutical industry urgently needs to increase investment in new medicines and improve the regulatory environment to avoid losing market share, with the EFPIA warning that without action, Europe could face a larger trade deficit.
See More
Europe's Pharmaceutical Market Share Declines Amid U.S. and China Competition
- Dramatic Market Share Decline: Over the past 35 years, Europe's share of global R&D has plummeted from nearly 50% to 26%, while the U.S. share has surged to 55%, indicating a significant decline in Europe's competitiveness in the pharmaceutical sector, compelling companies to shift investments towards the U.S. and China.
- Significant Policy Impact: The U.S. has imposed new tariffs of up to 100% on branded drugs, which, while limited in immediate impact on companies without price agreements, intensifies competitive pressure on Europe's pharmaceutical industry, prompting firms to reassess their investments in Europe.
- Shift in Innovation Centers: China has emerged as a biotech innovation hub, with global pharmaceutical companies increasingly looking to the country for R&D; a decade ago, Chinese-developed molecules accounted for just 4% of the global pipeline, but now they represent nearly a third, showcasing China's growing advantage in biopharma.
- Industry Calls for Change: The European pharmaceutical sector faces a risk of an €88 billion trade shortfall, prompting industry experts to advocate for increased investment in new medicines and improved regulatory environments to maintain competitiveness and ensure faster patient access to drugs.
See More
TSMC Reports Record Q1 Revenue Driven by AI Demand
- Significant Revenue Growth: TSMC reported a record first-quarter revenue of $35.6 billion, reflecting a 35% year-on-year increase that surpassed analyst expectations, showcasing the company's robust performance in the global semiconductor market, particularly driven by AI demand.
- Margin Expectations Rise: Analysts project that TSMC's gross margins could reach an astonishing 64% when full earnings are released on April 16, further solidifying its leadership in high-end chip manufacturing and boosting investor confidence.
- Intensifying Market Competition: As tech giants like Alphabet and Arm pivot to designing custom internal silicon, TSMC's unique manufacturing capabilities position it as a critical partner for these companies, ensuring its competitive edge in an increasingly crowded market.
- Optimistic Future Outlook: Market attention now shifts to ASML's upcoming earnings report, as the Dutch lithography giant provides essential machinery for TSMC to maintain its lead over rivals, making its performance crucial for TSMC's future growth potential.
See More
URTH ETF 52-Week Price Analysis
- Price Range Analysis: URTH ETF's 52-week low is $140.22 per share, with a high of $192.84, and the latest trade at $186.76 indicates stability near the high, potentially attracting investor interest in price fluctuations.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable technical insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights those experiencing significant inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets and market sentiment.
See More
Intensifying Competition in India's Weight-Loss Drug Market
- Market Share Shift: According to Pharmarack data, Eli Lilly's market share in India's GLP-1 weight-loss drug sector fell from 61% in March to 56%, while rival Novo Nordisk maintained a steady 25%, indicating fierce market competition.
- Patent Expiry Impact: The expiration of semaglutide's patent has led 13 Indian generic companies to launch 26 new brands rapidly, resulting in a more significant sales hit for Eli Lilly, with experts predicting further erosion for its tirzepatide-based products.
- Escalating Price Wars: In addition to launching cheaper generics, Novo Nordisk has reduced prices for its Ozempic and Wegovy by 38% and 48%, respectively, aiming to maintain competitiveness in the Indian market and further narrowing the price gap with generics.
- Optimistic Market Outlook: The Indian GLP-1 market is expected to grow nearly five-fold to 50 billion rupees by 2030, with some bullish estimates exceeding $1.2 billion, reflecting strong demand for weight-loss and diabetes medications.
See More
Foundayo Receives FDA Approval and Launches Nationwide
- Drug Launch: Eli Lilly announced that its weight loss medication Foundayo™ (orforglipron) received FDA approval on April 1, 2026, and became available through LillyDirect® and telehealth providers on April 9, marking a significant advancement in the weight loss market.
- Pricing and Accessibility: Foundayo is priced at $149 per month for self-pay patients, while eligible commercially insured patients can pay as little as $25 per month with a savings card, demonstrating Lilly's commitment to reducing patient burden and expanding drug accessibility.
- Clinical Trial Results: In the ATTAIN-1 clinical trial, patients on the highest dose lost an average of 27.3 pounds (12.4%), compared to only 2.2 pounds (0.9%) in the placebo group, indicating a significant advantage in weight loss efficacy that could enhance market acceptance.
- Health Risks and Side Effects: Foundayo may cause serious side effects, including thyroid tumors, requiring patients to be vigilant for symptoms; nevertheless, the drug's effectiveness and convenience continue to attract many seeking weight loss solutions.
See More
European Pharma Industry Faces Competitive Pressures
- Increased Market Competition: The European pharmaceutical industry is facing significant competitive pressures due to President Trump's drug pricing policies and the rise of China's biotech sector, leading to a shift in investments and impacting new drug launches.
- R&D Investment Shift: In 1990, Europe accounted for nearly half of global R&D, but this has plummeted to 26% today, while the U.S. share has risen to 55%, indicating a decline in Europe's position in global pharmaceutical innovation.
- Significant Policy Impact: The U.S. has imposed tariffs of up to 100% on branded drugs, which, while limited in immediate impact on companies without pricing agreements, adds to the competitive pressure on Europe's pharmaceutical sector, necessitating improvements in market conditions.
- Industry Calls for Reform: The European pharmaceutical industry urgently needs to increase investment in new medicines and improve the regulatory environment to avoid losing market share, with the EFPIA warning that without action, Europe could face a larger trade deficit.
See More
Europe's Pharmaceutical Market Share Declines Amid U.S. and China Competition
- Dramatic Market Share Decline: Over the past 35 years, Europe's share of global R&D has plummeted from nearly 50% to 26%, while the U.S. share has surged to 55%, indicating a significant decline in Europe's competitiveness in the pharmaceutical sector, compelling companies to shift investments towards the U.S. and China.
- Significant Policy Impact: The U.S. has imposed new tariffs of up to 100% on branded drugs, which, while limited in immediate impact on companies without price agreements, intensifies competitive pressure on Europe's pharmaceutical industry, prompting firms to reassess their investments in Europe.
- Shift in Innovation Centers: China has emerged as a biotech innovation hub, with global pharmaceutical companies increasingly looking to the country for R&D; a decade ago, Chinese-developed molecules accounted for just 4% of the global pipeline, but now they represent nearly a third, showcasing China's growing advantage in biopharma.
- Industry Calls for Change: The European pharmaceutical sector faces a risk of an €88 billion trade shortfall, prompting industry experts to advocate for increased investment in new medicines and improved regulatory environments to maintain competitiveness and ensure faster patient access to drugs.
See More
TSMC Reports Record Q1 Revenue Driven by AI Demand
- Significant Revenue Growth: TSMC reported a record first-quarter revenue of $35.6 billion, reflecting a 35% year-on-year increase that surpassed analyst expectations, showcasing the company's robust performance in the global semiconductor market, particularly driven by AI demand.
- Margin Expectations Rise: Analysts project that TSMC's gross margins could reach an astonishing 64% when full earnings are released on April 16, further solidifying its leadership in high-end chip manufacturing and boosting investor confidence.
- Intensifying Market Competition: As tech giants like Alphabet and Arm pivot to designing custom internal silicon, TSMC's unique manufacturing capabilities position it as a critical partner for these companies, ensuring its competitive edge in an increasingly crowded market.
- Optimistic Future Outlook: Market attention now shifts to ASML's upcoming earnings report, as the Dutch lithography giant provides essential machinery for TSMC to maintain its lead over rivals, making its performance crucial for TSMC's future growth potential.
See More
URTH ETF 52-Week Price Analysis
- Price Range Analysis: URTH ETF's 52-week low is $140.22 per share, with a high of $192.84, and the latest trade at $186.76 indicates stability near the high, potentially attracting investor interest in price fluctuations.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable technical insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights those experiencing significant inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets and market sentiment.
See More
Intensifying Competition in India's Weight-Loss Drug Market
- Market Share Shift: According to Pharmarack data, Eli Lilly's market share in India's GLP-1 weight-loss drug sector fell from 61% in March to 56%, while rival Novo Nordisk maintained a steady 25%, indicating fierce market competition.
- Patent Expiry Impact: The expiration of semaglutide's patent has led 13 Indian generic companies to launch 26 new brands rapidly, resulting in a more significant sales hit for Eli Lilly, with experts predicting further erosion for its tirzepatide-based products.
- Escalating Price Wars: In addition to launching cheaper generics, Novo Nordisk has reduced prices for its Ozempic and Wegovy by 38% and 48%, respectively, aiming to maintain competitiveness in the Indian market and further narrowing the price gap with generics.
- Optimistic Market Outlook: The Indian GLP-1 market is expected to grow nearly five-fold to 50 billion rupees by 2030, with some bullish estimates exceeding $1.2 billion, reflecting strong demand for weight-loss and diabetes medications.
See More
